The private sector and pharmaceutical industry in Africa
Providing access to quality medicines still poses a number of challenges in Africa. Distribution channels are often fragmented, with a large number of intermediaries or parallel channels, which often fuel counterfeiting – a real public health issue. For example, it is estimated that some 60% of medicines bought in the Gulf of Guinea are classified as “SF” (substandard and falsified) by the World Health Organization (WHO). Furthermore, the problem does not only affect Africa as 10% of all the medicines in circulation around the world could be “SF”.
Lire la revue SP&DMehdi Tanani, Senior Investment Officer and Head of Proparco’s Healthcare division, sets out the major issues tackled in this edition of the magazine.
This new edition of Private Sector & Development tackles all of these issues and attempts to come up with a few pointers and solutions for the future. It lets researchers, associations and public health organisations give their own views and recount their experiences: the whole issue of patents, for example, and private African start-ups such mPharma and Pharmivoire Nouvelle, a pioneering local producer of pharma products in Côte d’Ivoire.published on2018
on the same regionGovernancePrivate Sector and Developmentpublished onProparco sectoral bookletpublished onAFD Annual Reportspublished onProparco annual reportspublished onPrivate Sector and Developmentpublished onVideospublished on
on the same topicVideospublished onPrivate Sector and Developmentpublished onVideospublished onPrivate Sector and Developmentpublished on